Optimal Treatment Strategies for Anal Cancer

Ahmed, Shahab; Eng, Cathy

doi:10.1007/s11864-014-0298-0

Cited by 6 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 Their individual effect on the development of anal SCC is difficult to assess due to the prevalence of HPV and a higher risk of contracting HPV in patients who are HIV positive. 23 In this study, we examined the expression of macroH2A2 by immunohistochemistry staining of AIN and anal SCC samples in association with the status of HIV and HPV infections.…”

Section: Introductionmentioning

confidence: 99%

Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm

Miyai

Sporn

et al. 2015

J Clin Pathol

View full text Add to dashboard Cite

AimsThe macroH2A histone variants are epigenetic marks for inactivated chromatin. In this study, we examined the expression of macroH2A2 in anal neoplasm from anal intraepithelial neoplasia (AIN) to anal squamous cell carcinoma (SCC).MethodsAIN and anal SCC samples were analysed for macroH2A2 expression, HIV and human papilloma virus (HPV). The association of macroH2A2 expression with clinical grade, disease recurrence, overall survival and viral involvement was determined.ResultsmacroH2A2 was expressed in normal squamous tissue and lower grade AIN (I and II). Expression was lost in 38% of high-grade AIN (III) and 71% of anal SCC (p=0.002). Patients with AIN with macroH2A2-negative lesions showed earlier recurrence than those with macroH2A2-positive neoplasm (p=0.017). With anal SCC, macroH2A2 loss was more prevalent in the HPV-negative tumours.ConclusionsLoss of histone variant macroH2A2 expression is associated with the progression of anal neoplasm and can be used as a prognostic biomarker for high-grade AIN and SCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm

Miyai

Sporn

et al. 2015

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…However, its incidence is rising annually in both genders in the general population [2]- [4]. Rates of anal cancer in at-risk groups, principally men who have sex with men (MSM) and persons infected by the human immunodeficiency virus (HIV), are considerably higher than those described in the healthy population [5]- [8]. Although the incidence of other virus-associated malignancies has decreased in HIV-infected patients since antiretroviral therapy (ART) became available, the incidence of anal cancer has not.…”

Section: Introductionmentioning

confidence: 99%

Anal Invasive Squamous Cell Cancer and Human Papillomavirus Distribution in HIV-Infected and Non-HIV-Infected Individuals

Darwich¹,

Videla²,

Cañadas³

et al. 2014

IJCM

View full text Add to dashboard Cite

Invasive-squamous-cell-cancer (ISCC) of the anal canal is an uncommon disease. Human papillomavirus (HPV) is the etiological agent of most of types of ISCC. The incidence of ISCC has been increasing in HIV-infected individuals, even after the introduction of highly active antiretroviral therapy. The aim of this study was to analyze biopsy specimens from patients diagnosed with ISCC at a tertiary hospital from 1983 to 2012 in order to detect HPV-DNA. Methods: Formaldehydefixed, paraffin-embedded specimens from patients with ISCC underwent HPV-DNA genotyping using multiplex PCR assay. Results: A total of 31 cases were collected; 10 were HIV-infected (9 men, 1 woman) and 21 non-HIV-infected (11 men, 10 women). HPV infection was detected in 87.5% (7/8) of the HIV-infected patients (DNA from 2 biopsies was degraded) and 76.2% (16/21) of non-HIVinfected individuals. Multiple-type infections were only found in 28.6% (2/7) of the HIV-infected * Corresponding author. L. Darwich et al. 1156 patients (no multiple-type infections in non-HIV-infected individuals). The most prevalent type was HPV-16: 50% (4/8) in the HIV-infected group (57% [4/7] of the HPV-positive samples) and 66.7% (14/21) in the non-HIV-infected group (87.5% (14/16) of the HPV-positive samples). Remarkably, 37.5% (3/8) of the HIV-infected group had high-risk HPV types not included in the vaccines (HPV-33, 51, 52, and 66) compared with 4.8% in the non-HIV-infected group (1/21, HPV-52). All cases of anal ISCC in HIV-infected patients were recorded in the highly active antiretroviral therapy era. Conclusion: HIV-infected patients presented anal ISCC with a higher proportion of high-risk HPV types not covered by the conventional vaccines than non-HIV-infected individuals.

show abstract